<DOC>
	<DOCNO>NCT00002836</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know treatment regimen effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy plus filgrastim filgrastim alone treat woman undergo peripheral stem cell transplantation stage II , stage III , metastatic breast cancer .</brief_summary>
	<brief_title>Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether high dose chemotherapy addition growth factor increase yield filgrastim mobilize progenitor cell . II . Determine kinetics hematopoietic reconstitution follow myeloablative therapy mobilize blood stem cell transplantation . III . Determine whether use high dose chemotherapy addition growth factor mobilization stem cell reduce risk relapse measure time progression responsive relapse breast cancer patient receive autologous peripheral blood stem cell bone marrow transplant . IV . Determine morbidity cost difference use high dose chemotherapy plus growth factor compare growth factor alone mobilization peripheral blood progenitor treatment breast cancer high dose chemotherapy . OUTLINE : Patients randomize 2 group . Group 1 patient undergo CVP chemotherapy treatment vein ( IV ) day 1-3 , cyclophosphamide ( CTX ) , etoposide , cisplatin . Filgrastim SC ( subcutaneously ) give day 4 every 12 hour completion apheresis . Group 2 patient receive filgrastim SC give day 1 every 12 hour completion apheresis . Stem cell remove begin day 4 maximum 6 day . Upon recovery hematopoiesis patient receive high IV dose CBT chemotherapy CTX , carmustine , thiotepa 3 day , follow 4 day later autologous stem cell reinfusion . Beginning day reinfusion , filgrastim give bid WBC reach safe level . Patients follow 90 day posttransplant , follow indefinitely antitumor response time progression . PROJECTED ACCRUAL : This study include 218 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Female patient Stage II , III IV breast carcinoma remission , eligible protocol high priority ( DM89102 ) Stage II breast cancer must spread least 10 axillary node ; patient fewer 10 node must extranodal extension Patients great 75 % positive node tumor eligible No bone marrow involvement tumor standard histopathological exam bilateral iliac marrow biopsies 2 week prior study Prior normalization marker need patient elevated tumor marker ( e.g. , CEA ) Metastatic disease patient must documentation verify least 50 % reduction sit disease , except bone Stable bone metastasis measure via bone scan eligible Responsive disease large tumor burden enter high risk BMT protocol ( 93090 ) PATIENT CHARACTERISTICS : Age : 18 65 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 No hematopoietic growth factor treatment Hepatic : Bilirubin , SGOT , SGPT le 2 time normal Renal : Estimated creatinine clearance great 60 mL/min Cardiovascular : Normal ejection fraction Pulmonary : DLCO great 50 % predict Other : Not HIV positive Not pregnant 2 week prior study No comorbid condition place patient high risk complication No prior active infection No history untreated central nervous system ( CNS ) disease No allergic response egg murine protein PRIOR CONCURRENT THERAPY : No concurrent involvement clinical trial effect engraftment Biologic therapy : No growth factor within 1 week Chemotherapy : No 2 chemotherapy regimen allow relapse metastatic disease Chemotherapy responsive disease prior study Stage II/III disease receive neoadjuvant chemotherapy allow least 4 positive node mastectomy No partial response chemotherapy le 50 % site except bone No prior chemotherapy treatment carmustine Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Mastectomy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent breast cancer</keyword>
</DOC>